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In their thought-provoking and well-documented review,
Tataranno et al. [1] have summarized the “new body” of
knowledge about antioxidant drugs for neonatal brain injury.
The authors, however, did not mention that D-Penicillamine
(DPA) therapy is being used in the neonatal period (treat-
ment in various forms of hyperbilirubinemia [2] and the
prevention of retinopathy of prematurity (ROP), which,
despite its peripheral location, the retina or neural portion of
the eye, is actually part of the central nervous system [3, 4])
ever since 1973. Our recently published case reports, together
with other convincing cases which participated in the long-
term (28–40 years) follow-up, suggested that DPA therapy
of newborn infants may have significant neuroprotective
effects in cases jeopardized by bilirubin-induced neurologic
dysfunction (BIND) or ROP [5]. This unexpected effect may
be related to DPA capability to alter the nitric oxide (NO)
system [6–9] and its strong antioxidant effects [10–12]. NO
synthesized in the central nervous system produces a myriad
of effects. For example, it plays a role in the control of blood
flow, learning and memory, neurotransmitter release, gene
expression, immune responsiveness, and cell survival. It is
also implicated in numerous pathologies such as Alzheimer’s
disease, Huntington’s disease, cerebral ischemia, and disor-
ders of the basal ganglia caused by metals (Wilson’s disease),
bilirubin (BIND), or other pathologic conditions (Parkinson-
ism). The use of chelation therapy for nonmetal overload
indications continues to be investigated. Furthermore, the
mechanism of DPA in the reduction of serum bilirubin is
based on the fact that this drug inhibits the rate limited
enzyme (heme oxigenase) in heme metabolism [13]. Because
those enzymes that play an important role in antioxidant
defense and drug metabolism (peroxidases, catalase, and
cytochrome P-450) are heme proteins, it can be assumed that
in preventing hyperbilirubinemia, ROP, and oxygen toxicity,
the mechanism of action of DPA is identical: the protection
of biomembranes against lipid peroxidation caused by free
radical. Low molecular weight disulfides are the major prod-
ucts of DPAmetabolism in humans.The oxidation of DPA in
vivo may also important in the mode of action of the drug
through simultaneous reduction of oxygen species. Finally,
we can say that DPA fulfills the criteria of a hybrid drug in
the neonatal period by its ability to modulate both oxidative
stress and NO pathway and can be a neuroprotective agent in
the pathophysiology of neurologic dysfunction [14].
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